Article

Rhodococcus canchipurensis sp. nov., a novel actinomycete isolated from a limestone deposit site in Manipur, India.

Yunnan Institute of Microbiology, Yunnan University, Kunming, 650091, PR China;
INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY (Impact Factor: 2.11). 02/2012; DOI: 10.1099/ijs.0.036087-0
Source: PubMed

ABSTRACT A novel actinobacterial strain, MBRL 353T, was isolated from a sample collected from a limestone quarry at Hundung, Manipur, India. The strain was characterized using polyphasic taxonomy. Comparison of 16S rRNA gene sequences of strain MBRL 353T and other Rhodococcus species showed sequence similarities ranging from 95.5 to 98.2%, while phylogenetic analysis indicated that strain MBRL 353T showed closest similarity to Rhodococcus triatomae IMMIB RIV-085T (98.2%) and Rhodococcus equi DSM 20307T (97.2%). DNA-DNA hybridization results, however, revealed that the DNA relatedness between MBRL 353T and type strains of R. triatomae DSM 44892T (43.4%) and R. equi DSM 20307T (33.4%) were well below the 70% delineating limit for species identification. Strain MBRL 353T contained meso-diaminopimelic acid as the diagnostic diamino acid, with galactose and arabinose in cell-wall hydrolysates. Mycolic acids were present. The major fatty acids were C16:0 (45.7%), C18:1ω9c (18.2%) and 10-methyl C18:0 (11.3%). The only menaquinone detected was MK-8(H2), while the major polar lipids were diphosphatidylglycerol (DPG), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylinositol mannoside (PIM) and one unknown phospholipids (PL). The G+C content of the genomic DNA was 69.2%. The phenotypic and genotypic data showed that strain MBRL 353T merits the recognition as a representative of a novel species of the genus Rhodococcus. It is proposed that the isolate should be classified in the genus Rhodococcus as a novel species Rhodococcus canchipurensis sp. nov. The type strain is MBRL 353T (=KCTC 19851T = JCM 17578T).

0 Bookmarks
 · 
115 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Actinobacteria are important sources of compounds for drug discovery and have attracted considerable pharmaceutical, chemical, agricultural and industrial interests. Actinobacteriological research is still in its infancy in India. Early work on actinobacteria started in the 20th century and mostly focused on studying the diversity, identification and screening for antibiotics, enzymes and enzyme inhibitors. Exploration of diverse habitats for the isolation of actinobacteria, have yielded till date 23 novel species. Screening of actinobacteria for antagonistic activity, has led to the discovery of four novel antibiotics. Research on enzymes mostly covered lipases, amylases, proteases, endoglucanases, a-galactosidases, pectin lyases, xylanases, L-asparaginases, L-glutaminase and cellulases. Research on exploiting actinobacteria for other purposes such as production of enzyme inhibitors, single cell protein, bioemulsifier and biosurfactants is still in the experimental stage. This review compiles the work done in last few years, with an emphasis on actinobacterial diversity and bioprospecting for pharmaceutically important compounds like antibiotics, enzymes and other important applications. The chemical creativity and biotechnological potential of Indian actinobacterial strains are yet to be fully explored. A national strategy is required consistent with the opportunities provided by CBD-Nagoya protocol.
    Indian journal of experimental biology 08/2013; 51(8):573-96. · 1.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bacterial lipid metabolism has long had a significant impact on the understanding of the basic lipid metabolic pathways, enzyme mechanisms and transcriptional regulation. The early work in the Escherichia coli system jump-started the investigation of fatty acid and phospholipid synthesis. A recent review by Dowhan [1] recounts these early days of discovery in bacterial lipid metabolism. For decades, E. coli was considered the paradigm for bacterial metabolism; however, the advent of the genomic era revealed that genes and enzymes of lipid metabolism painstakingly investigated in E. coli are not common to all bacteria. This realization has accelerated research into the great diversity in pathways, and fatty acid and phospholipid structures that occur in nature. This review attempts to capture and organize this diversity to provide an overview of lipid metabolism in prokaryotes as it stands today.
    Progress in lipid research 03/2013; · 10.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Actinobacteria are important sources of compounds for drug discovery, and has attracted considerable pharmaceutical, chemical, agricultural, industrial interests. Actinobacteriological research is still at its infancy in India. Early work on actinobacteria started in the 20th century and mostly focused on studying the diversity, identification and screening for antibiotics, enzymes and enzyme inhibitors. The chemical creativity and biotechnological potential of Indian actinobacterial strains are yet to be fully explored. A national strategy is required consistent with the opportunities provided by CBD-Nagoya protocol. Exploration of diverse habitats for the isolation of actinobacteria, have yielded till date 23 novel species. Screening of actinobacteria for antagonistic activity, has led to the discovery of four novel antibiotics. Research on enzymes mostly covered lipases, amylases, proteases, endoglucanases, α-galactosidases, pectin lyases, xylanases, L-asparaginases, L-glutaminase and cellulases. Research on exploiting actinobacteria for other purposes such as production of enzyme inhibitors, single cell protein, bioemulsifier and biosurfactants is still in the experimental stage. This review compiles the work done in last few years, with an emphasis on actinobacterial diversity and biospropecting for pharmaceutically important compounds like antibiotics, enzymes and other important applications.
    Indian journal of experimental biology 08/2013; 51:573-596. · 1.20 Impact Factor